Wellbutrin xl can you cut in half

Brompheniramine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Brompheniramine; Pseudoephedrine; Dextromethorphan: Major Bupropion is associated with a dose-related risk of seizures. Budesonide: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Budesonide; Formoterol: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids. Budesonide; Glycopyrrolate; Formoterol: Moderate Additive anticholinergic effects may be seen when glycopyrrolate is used concomitantly with bupropion. Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Buprenorphine: Moderate If concomitant use of buprenorphine and bupropion is warranted, monitor patients for the emergence of serotonin syndrome. Buprenorphine; Naloxone: Moderate If concomitant use of buprenorphine and bupropion is warranted, monitor patients for the emergence of serotonin syndrome.

Butabarbital: Moderate Bupropion may interact with drugs that induce hepatic microsomal isoenzyme function via CYP2B6 such as the barbiturates. Butalbital; Acetaminophen: Moderate Bupropion may interact with drugs that induce hepatic microsomal isoenzyme function via CYP2B6 such as the barbiturates. Butalbital; Acetaminophen; Caffeine: Moderate Bupropion is associated with a dose-related risk of seizures. Butalbital; Acetaminophen; Caffeine; Codeine: Moderate Bupropion is associated with a dose-related risk of seizures.

Caffeine: Moderate Bupropion is associated with a dose-related risk of seizures. Caffeine; Sodium Benzoate: Moderate Bupropion is associated with a dose-related risk of seizures. Calcium, Magnesium, Potassium, Sodium Oxybates: Major Use extreme caution when coadministering bupropion with other drugs that lower the seizure threshold, such as sodium oxybate. The risk of seizures with bupropion is dose related and is also related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold.

Consider these risks before initiating treatment If used together, use low initial doses of bupropion and increase the dose gradually. Cannabidiol: Moderate Consider a dose adjustment of bupropion when coadministered with cannabidiol. Carbamazepine: Moderate Bupropion should not be used by patients with a preexisting seizure disorder because it may lower the seizure threshold. Carbamazepine induces hepatic enzymes and may lower bupropion exposure.

Bupropion is a sensitive substrate of CYP2B6, and carbamazepine is a potent inducer for this enzyme. Monitor for signs of reduced bupropion efficacy during use together. Also monitor for any changes in seizure status if carbamazepine is used to treat seizures. Carbetapentane; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Carbidopa; Levodopa: Major Use bupropion cautiously in patients taking levodopa or combination drugs containing levodopa e. Both drugs are dopamine agonists; cumulative effects may result in central nervous system CNS toxicity. Adverse reactions reported with coadministration have included restlessness, agitation, tremor, ataxia, gait disturbance, vertigo, and dizziness.

If levodopa is used concurrently, low initial dosing and slow dosage titration of bupropion may be warranted. Carbidopa; Levodopa; Entacapone: Major Use bupropion cautiously in patients taking levodopa or combination drugs containing levodopa e. Carbinoxamine; Dextromethorphan; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Carbinoxamine; Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.

Carbinoxamine; Hydrocodone; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Carbinoxamine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Cariprazine: Major Bupropion is associated with a dose-related risk of seizures. Carvedilol: Minor Monitor for an increased incidence of carvedilol-related adverse effects if bupropion and carvedilol are used concomitantly.

Coadministration of bupropion and carvedilol may result in increased plasma concentrations of carvedilol. Carvedilol is a CYP2D6 substrate. Cenobamate: Major Increase the dosage of bupropion as needed when coadministered with cenobamate due to the potential for reduced efficacy of bupropion. Cetirizine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Inhibitors of this isoenzyme, like bupropion, would be expected to lead to an increase in cevimeline plasma concentrations. Chlophedianol; Dexchlorpheniramine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Chlordiazepoxide; Clidinium: Moderate Bupropion exhibits moderate anticholinergic effects. Clinicians should consider this when using antimuscarinics and other medications with anticholinergic activity in combination with bupropion.

Chlorpheniramine; Codeine: Moderate Concomitant use of codeine with bupropion may increase codeine plasma concentrations, but decrease the plasma concentration of the active metabolite, morphine, resulting in reduced efficacy or symptoms of opioid withdrawal. Chlorpheniramine; Dextromethorphan; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Chlorpheniramine; Dihydrocodeine; Phenylephrine: Moderate Concomitant use of dihydrocodeine with bupropion may increase dihydrocodeine plasma concentrations, but decrease the plasma concentration of the active metabolite, dihydromorphine, resulting in reduced efficacy or symptoms of opioid withdrawal. Chlorpheniramine; Dihydrocodeine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Chlorpheniramine; Guaifenesin; Hydrocodone; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Chlorpheniramine; Hydrocodone: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. Chlorpheniramine; Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.

Chlorpheniramine; Hydrocodone; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Chlorpheniramine; Ibuprofen; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Chlorpheniramine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Chlorpromazine: Major Bupropion is associated with a dose-related risk of seizures and may have an additive effect with phenothiazines on lowering the seizure threshold.

Low initial dosing and slow titration is recommended if this combination must be used. In addition, bupropion is a strong inhibitor of CYP2D6. Dosage reductions of chlorpromazine, a CYP2D6 substrate, may be needed during coadministration with bupropion.

Increased serum concentrations of chlorpromazine may result in QT prolongation, somnolence, anticholinergic effects, or orthostasis. Ciclesonide: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids. Cimetidine: Moderate Cimetidine has resulted in increased plasma concentrations of the active metabolites, threohydrobupropion and erythrobupropion, but the clinical significance is not known.

Citalopram: Moderate A pharmacokinetic interaction has been observed between bupropion and citalopram. Citalopram did not affect the kinetics of bupropion or its metabolites. Clopidogrel: Moderate Dosage adjustment of bupropion may be necessary during coadministration with clopidogrel. Concomitant use may increase bupropion exposure but decrease hydroxybupropion exposure.

Clozapine: Major Monitor for evidence of clozapine-related adverse reactions and consider a clozapine dose reduction if necessary when coadministered with bupropion. If bupropion is discontinued after dose adjustments are made, monitor for lack of clozapine affect and consider increasing the clozapine dose if necessary.

Concurrent use may result in increased clozapine exposure due to inhibition of CYP2D6 metabolism by bupropion. Treatment with clozapine has been associated with QT prolongation, torsade de pointes TdP , cardiac arrest, and sudden death. Elevated plasma concentrations of clozapine may potentially increase the risk of life-threatening arrhythmias, sedation, anticholinergic effects, seizures, orthostasis, or other adverse effects.

Furthermore, bupropion is associated with a dose-related risk of seizures; this risk may be increased by antipsychotics. Cobicistat: Moderate Caution is warranted when cobicistat is administered with bupropion as there is a potential for elevated cobicistat concentrations.

Cocaine: Major Bupropion is associated with a dose-related risk of seizures. Extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as cocaine. This is of particular concern in those with excessive cocaine use i. Patients should be closely monitored if this combination is necessary.

Codeine: Moderate Concomitant use of codeine with bupropion may increase codeine plasma concentrations, but decrease the plasma concentration of the active metabolite, morphine, resulting in reduced efficacy or symptoms of opioid withdrawal. Codeine; Guaifenesin: Moderate Concomitant use of codeine with bupropion may increase codeine plasma concentrations, but decrease the plasma concentration of the active metabolite, morphine, resulting in reduced efficacy or symptoms of opioid withdrawal.

Codeine; Guaifenesin; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Codeine; Phenylephrine; Promethazine: Major Bupropion is associated with a dose-related risk of seizures and may have an additive effect with phenothiazines on lowering the seizure threshold.

Dosage reductions of promethazine, a CYP2D6 substrate, may be needed during coadministration with bupropion. Increased serum concentrations of promethazine may result in extrapyramidal symptoms, somnolence, or other adverse effects. Codeine; Promethazine: Major Bupropion is associated with a dose-related risk of seizures and may have an additive effect with phenothiazines on lowering the seizure threshold.

Corticosteroids: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids. Cortisone: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Cyclobenzaprine: Major Concurrent use of cyclobenzaprine with bupropion increases the possibility of developing serotonin syndrome. If these drugs must be used together, closely monitor the patient for signs and symptoms of serotonin syndrome. If such a reaction develops, immediately discontinue both drugs. Additionally, cyclobenzaprine possesses antimuscarinic properties, which can cause dry mouth, urinary difficulties and slowing of gastrointestinal motility.

If used with other drugs with antimuscarinic properties, such as bupropion, anticholinergic side effects can be additive. Particular attention should be paid to GI problems because of the possible development of paralytic ileus.

Dabrafenib: Major The concomitant use of dabrafenib and bupropion may lead to decreased bupropion concentrations and loss of efficacy. Use of an alternative agent is recommended. If concomitant use of these agents is unavoidable, monitor patients for loss of bupropion efficacy. In vitro, dabrafenib is an inducer of CYP2B6 via activation of the pregnane X receptor and constitutive androstane receptor nuclear receptors.

Bupropion is a sensitive CYP2B6 substrate. Dalfampridine: Moderate Due to additive risks for seizure, extreme caution when coadministering bupropion with other drugs that lower seizure threshold e. Use low initial doses and increase the dose gradually. Monitor for seizure activity. Consider benefits against the risk of seizures. Additionally, bupropion inhibits OCT2 in vitro, but the clinical relevance is not certain.

Concurrent treatment with OCT2 inhibitors, such as bupropion, may cause increased exposure to dalfampridine. Elevated levels of dalfampridine increase the risk of seizures.

The potential benefits of taking OCT2 inhibitors concurrently with dalfampridine should be considered against the risk of seizures in these patients. In addition, bupropion is associated with moderate anticholinergic effects which could be additive when coadministered with darifenacin.

Patients should be monitored for increased anticholinergic effects or other adverse effects when these two drugs are coadministered. Dosage adjustments may be necessary. Darunavir; Cobicistat: Moderate Caution is warranted when cobicistat is administered with bupropion as there is a potential for elevated cobicistat concentrations. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: Moderate Caution is warranted when cobicistat is administered with bupropion as there is a potential for elevated cobicistat concentrations.

Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Moderate Concurrent administration of bupropion with ritonavir results in decreased concentrations of bupropion and its active metabolite. According to the manufacturers of bupropion, increased doses of bupropion may be necessary during concurrent therapy; however, the maximum recommended dose of bupropion should not be exceeded. Closely monitor bupropion efficacy if these drugs are given together. Ritonavir induces CYP2B6, which is responsible for bupropion's metabolism.

Deflazacort: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Desloratadine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. The systemic exposure of alpha- and beta-HTBZ may be increased resulting in an increase in deutetrabenazine-related adverse reactions, like QT prolongation and drowsiness.

Dexamethasone: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids. Dexbrompheniramine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Dextroamphetamine: Major Bupropion is associated with a dose-related risk of seizures.

Dextromethorphan; Guaifenesin; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Dicyclomine: Moderate Additive anticholinergic effects may be seen when dicyclomine is used concomitantly with other drugs that possess anticholinergic properties, such as bupropion. Diethylpropion: Major Drugs which may lower the seizure threshold, such as diethylpropion, should be used with great caution or avoided in patients taking bupropion.

The manufacturer recommends low initial dosing and slow dosage titration of bupropion if this combination must be used concurrently; the patient should be closely monitored. Digoxin: Moderate Plasma digoxin concentrations and the patient's clinical response to digoxin therapy should be monitored during concurrent use with bupropion, due to the potential for decreased systemic exposure to digoxin. When a single oral dose of 0. Dihydrocodeine; Guaifenesin; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Diphenhydramine; Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. Diphenoxylate; Atropine: Moderate The anticholinergic effects of atropine may be enhanced when combined with other drugs with moderate to significant anticholinergic effects including bupropion.

Dorzolamide; Timolol: Minor Monitor for an increased incidence of timolol-related adverse effects if bupropion and timolol are used concomitantly. Doxercalciferol: Moderate CYP enzyme inhibitors, like bupropion, may inhibit the hydroxylation of doxercalciferol, thereby decreasing the formation of the active metabolite and thus, decreasing efficacy.

Patients should be monitored for a decrease in efficacy if cytochrome P inhibitors are coadministered with doxercalciferol. Clinically significant interactions have been reported when doxorubicin was coadministered with inhibitors of CYP2D6, resulting in increased concentration and clinical effect of doxorubicin. Avoid coadministration of bupropion and doxorubicin if possible.

If not possible, closely monitor for increased side effects of doxorubicin including myelosuppression and cardiotoxicity. Duloxetine: Moderate Monitor for increased duloxetine-related adverse effects if coadministered with bupropion. Concurrent use may result in increased duloxetine exposure resulting in excessive serotonin activity.

Tamsulosin is extensively metabolized by CYP2D6 hepatic enzymes. In clinical evaluation, concomitant treatment with a strong CYP2D6 inhibitor resulted in increases in tamsulosin exposure. If concomitant use in necessary, monitor patient closely for increased side effects. Healthcare providers are advised to increase the dose of bupropion based on clinical response during concurrent use with efavirenz; however, the maximum recommended dose of bupropion should not be exceeded.

Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide: Moderate Caution is warranted when cobicistat is administered with bupropion as there is a potential for elevated cobicistat concentrations.

Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate: Moderate Caution is warranted when cobicistat is administered with bupropion as there is a potential for elevated cobicistat concentrations.

Caution is recommended when administering encainide with CYP2D6 inhibitors, such as bupropion, since encainide exhibits a narrow therapeutic range and large increases in serum concentrations may be associated with severe adverse reactions. Ergotamine; Caffeine: Moderate Bupropion is associated with a dose-related risk of seizures. Ethanol: Major Bupropion is associated with a dose-related risk of seizures. The use of alcohol or the abrupt discontinuation of ethanol should be avoided in patients taking bupropion.

During post-marketing use of bupropion, some patients who were drinking alcohol reported reduced alcohol tolerance. Ethotoin: Moderate When anticonvulsants are used for the purpose of treating epilepsy versus use in mood disorders or neuropathic pain or other non-epilepsy conditions , bupropion should not be used since bupropion lowers the seizure threshold.

Bupropion may be combined with anticonvulsant treatments with caution when an anticonvulsant is used for non-epilepsy conditions e. Bupropion may interact pharmacokinetically with anticonvulsant drugs that induce hepatic microsomal isoenzyme function such as phenytoin as well as other hydantoins like fosphenytoin or ethotoin. Monitor for reduced bupropion efficacy. Felbamate: Major Bupropion should not be used by patients taking anticonvulsants for seizures because it may decrease the seizure threshold.

Bupropion may also interact pharmacokinetically with anticonvulsant drugs that induce hepatic microsomal isoenzyme function. Fenfluramine: Moderate Use fenfluramine and bupropion with caution due to an increased risk of serotonin syndrome. Monitor patients for the emergence of serotonin syndrome. Fentanyl: Moderate If concomitant use of fentanyl and bupropion is warranted, monitor patients for the emergence of serotonin syndrome.

Fexofenadine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Flavoxate: Moderate Bupropion exhibits moderate anticholinergic effects.

Clinicians should keep this in mind when using antimuscarinics and other medications with anticholinergic activity in combination with bupropion. Caution is recommended when administering flecainide with CYP2D6 inhibitors, such as bupropion; flecainide exhibits a narrow therapeutic range and large increases in serum concentrations may be associated with severe adverse reactions.

Fludrocortisone: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Flunisolide: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids. Coadministration of bupropion with medications that are metabolized by CYP2D6 should be approached with caution.

Fluphenazine: Major Bupropion is associated with a dose-related risk of seizures and may have an additive effect with phenothiazines on lowering the seizure threshold. Dosage reductions of fluphenazine, a CYP2D6 substrate, may be needed during coadministration with bupropion. Increased serum concentrations of fluphenazine may result in extrapyramidal symptoms, somnolence, or other adverse effects. Fluticasone: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Fluticasone; Salmeterol: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids. Fluticasone; Umeclidinium; Vilanterol: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Fluticasone; Vilanterol: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

In addition, in vitro studies suggest that fluvoxamine inhibits the hydroxylation of bupropion. Formoterol; Mometasone: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids. Fosphenytoin: Moderate When anticonvulsants are used for the purpose of treating epilepsy versus use in mood disorders or neuropathic pain or other non-epilepsy conditions , bupropion should not be used since bupropion lowers the seizure threshold.

Gabapentin: Moderate A reduction in seizure threshold has been reported following concomitant administration of pemoline with anticonvulsant agents. Gefitinib: Moderate Monitor for an increase in gefitinib-related adverse reactions if coadministration with bupropion is necessary; the risk is increased in CYP2D6 poor metabolizers. In healthy CYP2D6 poor metabolizers, the concentration of O-desmethyl gefitinib was not measurable and mean exposure to gefitinib was 2-fold higher compared to extensive metabolizers.

The impact of CYP2D6 inhibitors on gefitinib pharmacokinetics has not been evaluated; however, the manufacturer recommends precautions based on exposure in patients with poor CYP2D6 metabolism. Glycopyrrolate: Moderate Additive anticholinergic effects may be seen when glycopyrrolate is used concomitantly with bupropion. Glycopyrrolate; Formoterol: Moderate Additive anticholinergic effects may be seen when glycopyrrolate is used concomitantly with bupropion.

Guaifenesin; Hydrocodone: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.

Guaifenesin; Hydrocodone; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Guaifenesin; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Guanfacine: Moderate There is one case report that describes a grand mal seizure that occurred in a child of 10 years of age receiving guanfacine and bupropion concurrently.

It is not possible, based on this limited report, to determine if guanfacine was a contributor to the event. Causality has not been established. Haloperidol: Major Bupropion is associated with a dose-related risk of seizures. In addition, bupropion and hydroxybupropion, the major active metabolite, are inhibitors of CYP2D6 in vitro. Coadministration of bupropion with medications that are metabolized by the CYP2D6 isoenzyme, such as haloperidol, should be approached with caution.

Dosage reductions of haloperidol may be needed. Conversely, if bupropion therapy is discontinued, the antipsychotic dosage may need to be increased in some patients. Homatropine; Hydrocodone: Moderate Additive anticholinergic effects may be seen when homatropine is used concomitantly with bupropion.

Hydantoins: Moderate When anticonvulsants are used for the purpose of treating epilepsy versus use in mood disorders or neuropathic pain or other non-epilepsy conditions , bupropion should not be used since bupropion lowers the seizure threshold.

Hydrocodone: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.

Hydrocodone; Ibuprofen: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. Hydrocodone; Phenylephrine: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.

Hydrocodone; Potassium Guaiacolsulfonate: Moderate Concomitant use of hydrocodone with bupropion may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Hydrocodone; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Hydrocortisone: Moderate Because bupropion is associated with a dose-related risk of seizures, extreme caution is recommended during concurrent use of other drugs that may lower the seizure threshold such as systemic corticosteroids.

Hydromorphone: Moderate Excessive use of opioid agonists e. Hyoscyamine: Moderate Additive anticholinergic effects may be seen when hyoscyamine is used concomitantly with bupropion. Hyoscyamine; Methenamine; Methylene Blue; Phenyl Salicylate; Sodium Biphosphate: Contraindicated Due to an increased risk of hypertensive reactions, treatment initiation with bupropion is contraindicated in patients currently receiving intravenous methylene blue. Ibuprofen; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures.

Iloperidone: Major Reduce the iloperidone dose by one-half if coadministered with bupropion. If bupropion is discontinued, increase the iloperidone dose to the previous level. Increased iloperidone exposure may occur with concurrent use. Additionally, bupropion is associated with a dose-related risk of seizures.

Iloperidone is a CYP2D6 substrate. Coadministration of other strong CYP2D6 inhibitors increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by up to 3-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half.

Indacaterol; Glycopyrrolate: Moderate Additive anticholinergic effects may be seen when glycopyrrolate is used concomitantly with bupropion. Iobenguane I Major Discontinue bupropion for at least 5 half-lives before the administration of the dosimetry dose or a therapeutic dose of iobenguane I Do not restart bupropion until at least 7 days after each iobenguane I dose. Drugs that reduce catecholamine uptake or deplete catecholamine stores, such as bupropion, may interfere with iobenguane I uptake into cells and interfere with dosimetry calculations resulting in altered iobenguane I efficacy.

Isavuconazonium: Moderate Caution and close monitoring are advised when administering isavuconazonium concurrently with buproprion, as decreased buproprion serum concentrations may result. If decreased bupropion efficacy is noted, it may be necessary to increase the dose not to exceed the maximum recommended dose. Isavuconazole, the active moiety of isavuconazonium, is an inducer of hepatic isoenzyme CYP2B6; bupropion is metabolized by this enzyme. Isocarboxazid: Contraindicated Monoamine oxidase inhibitors MAOIs intended to treat psychiatric disorders are contraindicated for use with bupropion or within 14 days of discontinuing treatment with bupropion.

Conversely, bupropion should not be initiated within 14 days of stopping an MAOI. There is an increased risk of hypertensive reactions when bupropion is used concurrently with other drugs that inhibit the reuptake of dopamine or norepinephrine or inhibit their metabolism, such as MAOIs.

Pharmacokinetic studies describe patients who developed subtherapeutic bupropion serum concentrations when enzyme-inducing agents were added. In healthy volunteers, coadministration of bupropion with rifampin reduced the mean AUC of bupropion by 3-fold and the mean half-life from Isoniazid, INH; Rifampin: Moderate Bupropion may interact with drugs that induce hepatic microsomal isoenzyme function such as rifampin.

Ivosidenib: Moderate Monitor for loss of efficacy of bupropion during coadministration of ivosidenib. A bupropion dose increase may be necessary; do not exceed the maximum recommended dose.

Lacosamide: Moderate Bupropion should not be used by patients with a preexisting seizure disorder because it may lower the seizure threshold. Lamotrigine: Moderate Bupropion should not be used by patients with a preexisting seizure disorder because it may lower the seizure threshold. Lasmiditan: Moderate Serotonin syndrome may occur during coadministration of lasmiditan and bupropion. Inform patients taking this combination of the possible increased risk and monitor for the emergence of serotonin syndrome particularly after a dose increase or the addition of other serotonergic medications to an existing regimen.

Discontinue all serotonergic agents if serotonin syndrome occurs and implement appropriate medical management. Lemborexant: Moderate Monitor for loss of efficacy of bupropion during coadministration of lemborexant as concurrent use may decrease bupropion exposure.

A bupropion dose adjustment may be necessary; do not exceed maximum dose for the specific product prescribed. Levetiracetam: Moderate Bupropion should not be used by patients with a preexisting seizure disorder because it may lower the seizure threshold. Levodopa: Major Use bupropion cautiously in patients taking levodopa or combination drugs containing levodopa e.

Linezolid: Contraindicated Due to an increased risk of hypertensive reactions, treatment initiation with bupropion is contraindicated in patients currently receiving linezolid, an antibiotic that is also a non-selective monoamine oxidase MAO inhibitor. Conversely, in patients receiving bupropion and requiring urgent treatment with linezolid, bupropion should be discontinued immediately and linezolid therapy initiated only if acceptable alternatives are not available and the potential benefits of linezolid outweigh the risks.

The patient should be monitored for hypertensive reactions for two weeks or until 24 hours after the last dose of linezolid, whichever comes first. Bupropion may be re-initiated 24 hours after the last dose of linezolid. Lisdexamfetamine: Major The risk of seizures from the use of bupropion may be increased with concomitant use of CNS stimulants that may induce seizures, including the lisdexamfetamine.

Lofexidine: Moderate Monitor for orthostatic hypotension and bradycardia during concurrent use of lofexidine and bupropion. Coadministration may increase lofexidine exposure. If these drugs are used together, monitor for loperamide-associated adverse reactions, such as CNS effects and cardiac toxicities i.

Lopinavir; Ritonavir: Moderate Concurrent administration of bupropion with ritonavir results in decreased concentrations of bupropion and its active metabolite. Loratadine; Pseudoephedrine: Major Bupropion is associated with a dose-related risk of seizures. Lorcaserin: Moderate Based on the mechanism of action of lorcaserin and the theoretical potential for serotonin syndrome, use with extreme caution in combination with other drugs that may affect the serotonergic neurotransmitter systems, including, bupropion.

If your doctor does decide to decrease your bupropion dose, it would be better to prescribe the mg tablet that is available. Your doctor may decide to change your medication altogether because of the side effects of bupropion XL that you are experiencing. Jennifer Oliver is a licensed immunizing pharmacist in Florida. Other than her passion for pharmacy, she loves traveling and meeting new people.

Questions Articles Drugs Interactions Ask a pharmacist. Published: May 15, Last Updated: Oct 27, Answered By: Dr. Jennifer Oliver Pharm. May 14, Was this article helpful? We'll never share your email with anyone else. Submit Close. Related Questions. Why is it recommended to not split tablets of tadalafil? Different brands may not work the same way. You may take this medicine with or without food.

But if you have nausea, take the medicine with food. A part of the extended-release tablet may pass into your stool. This is normal and is nothing to worry about. If you use this medicine to prevent depression with seasonal affective disorder, take it during the autumn season before your symptoms start.

Continue using the medicine through the winter season and until early spring. The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine.

If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. If you miss a dose of this medicine, skip the missed dose and go back to your regular dosing schedule. Do not double doses. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.